CL2023002497A1 - Uso de inhibidores de bet como tratamiento para la mielofibrosis - Google Patents

Uso de inhibidores de bet como tratamiento para la mielofibrosis

Info

Publication number
CL2023002497A1
CL2023002497A1 CL2023002497A CL2023002497A CL2023002497A1 CL 2023002497 A1 CL2023002497 A1 CL 2023002497A1 CL 2023002497 A CL2023002497 A CL 2023002497A CL 2023002497 A CL2023002497 A CL 2023002497A CL 2023002497 A1 CL2023002497 A1 CL 2023002497A1
Authority
CL
Chile
Prior art keywords
treatment
myelofibrosis
beta inhibitors
need
cancer
Prior art date
Application number
CL2023002497A
Other languages
English (en)
Inventor
Aronchik Ida
Valeria BELTRAN VALENCIA Roxxana
Soraya Carrancio Anton Maria
H Chang Henry
Coker Shodeinde
DAS Sharmila
Hope Filvaroff Ellen
GUARINOS MARHUENDA Carla
HANNA Bishoy
Liu Yu
Nikolova Zariana
Esposito Oriana
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of CL2023002497A1 publication Critical patent/CL2023002497A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)

Abstract

La presente divulgación proporciona métodos, composiciones farmacéuticas y kits para pacientes que precisan tratar el cáncer. Los métodos comprenden administrar a un paciente que lo necesite un inhibidor de BET (bromodominio y proteína extraterminal), o una sal farmacéuticamente aceptable del mismo, solo o en combinación con uno o más inhibidores de JAK. También se proporcionan medicamentos para su uso en el tratamiento del cáncer.
CL2023002497A 2021-02-25 2023-08-23 Uso de inhibidores de bet como tratamiento para la mielofibrosis CL2023002497A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21382163 2021-02-25
US202163232866P 2021-08-13 2021-08-13
US202263297098P 2022-01-06 2022-01-06

Publications (1)

Publication Number Publication Date
CL2023002497A1 true CL2023002497A1 (es) 2024-01-12

Family

ID=80786345

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002497A CL2023002497A1 (es) 2021-02-25 2023-08-23 Uso de inhibidores de bet como tratamiento para la mielofibrosis

Country Status (11)

Country Link
US (1) US20220265617A1 (es)
EP (1) EP4297750A1 (es)
JP (1) JP2024507938A (es)
KR (1) KR20230148208A (es)
AU (1) AU2022227673A1 (es)
CA (1) CA3206708A1 (es)
CL (1) CL2023002497A1 (es)
IL (1) IL304697A (es)
MX (1) MX2023009858A (es)
TW (1) TW202302095A (es)
WO (1) WO2022182857A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1951684T (pt) 2005-11-01 2016-10-13 Targegen Inc Inibidores de cinases de tipo biaril-meta-pirimidina
PT3184526T (pt) 2005-12-13 2018-12-19 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
US20080312259A1 (en) 2007-06-13 2008-12-18 Incyte Corporation SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
DK3466949T3 (da) * 2013-12-24 2021-03-15 Bristol Myers Squibb Co Tricyklisk forbindelse som anticancermidler
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US20220119370A1 (en) * 2018-09-07 2022-04-21 H. Lee Moffitt Cancer Center And Reseach Institute, Inc. Brd4-jak2 inhibitors
BR112021005518A2 (pt) 2018-09-25 2021-06-29 Impact Biomedicines, Inc. métodos para tratar distúrbios mieloproliferativos
US20230250068A1 (en) 2019-02-12 2023-08-10 Inpact Biomedicines, Inc. Crystalline forms of a jak2 inhibitor

Also Published As

Publication number Publication date
AU2022227673A1 (en) 2023-08-17
CA3206708A1 (en) 2022-09-01
JP2024507938A (ja) 2024-02-21
WO2022182857A1 (en) 2022-09-01
US20220265617A1 (en) 2022-08-25
IL304697A (en) 2023-09-01
KR20230148208A (ko) 2023-10-24
TW202302095A (zh) 2023-01-16
MX2023009858A (es) 2023-09-12
EP4297750A1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
UY38481A (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CL2017002481A1 (es) Terapia de combinación del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte progamada 1 (pd 1) para el tratamiento del cáncer
BR112021006458A2 (pt) composto de isoindolina, seu método de preparação, composição farmacêutica e uso
CR20140086A (es) Tratamientos de combinación para hepatitis c
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
SV2010003491A (es) 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
CO6390066A2 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP12012024A (es) Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CO2022015891A2 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
CU20090007A6 (es) Un compuesto farmacéutico y un proceso del mismo
CL2020000271A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
CL2023002497A1 (es) Uso de inhibidores de bet como tratamiento para la mielofibrosis
BR112018006572A2 (pt) terapia de combinação racional para o tratamento de câncer
BR112023022647A2 (pt) Derivado de 7-nitro-8-hidroxiquinolina, método de preparação do mesmo e uso médico do mesmo
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.